Exploiting cholera vaccines as a versatile antigen delivery platform

Biotechnology Letters

Volumn 30, Issue 4, 2008, Pages 571-579

  Silva, Anisia J ^a   Eko, Francis O ^a   Benitez, Jorge A ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen delivery; Cholera vaccines; Protein expression; Vaccine development

Indexed keywords

ANTIGENS; DISEASES; DRUG DELIVERY; GENE EXPRESSION; IMMUNOLOGY; TOXIC MATERIALS;

ANTIGEN DELIVERY; CHOLERA VACCINES; PROTEIN EXPRESSION; VACCINE DEVELOPMENT;

VACCINES;

BACTERIAL ANTIGEN; CHOLERA VACCINE;

CHOLERA; IMMUNOLOGY; REVIEW; VIBRIO CHOLERAE;

ANTIGENS, BACTERIAL; CHOLERA; CHOLERA VACCINES; VIBRIO CHOLERAE;

VIBRIO CHOLERAE;

EID: 43149102709     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-007-9594-0     Document Type: Review

References (74)

1. Albert MJ (1994) Vibrio cholerae O139 Bengal. J Clin Microbiol 32:2345-2349
2. Bäckström MM, Lebens F, Schödel F, Holmgren J (1994) Insertion of a HIV-neutralizing epitope in a surface-exposed internal region of the cholera toxin B subunit. Gene 149:211-217
3. Benitez JA, Spelbrink RG, Silva AJ et al (1997) Adherence of Vibrio cholerae to cultured differentiated human intestinal cells: an in vitro colonization model. Infect Immun 65:3474-3477
4. Benítez JA, García L, Silva AJ et al (1999) Preliminary assessment of the safety and immunogenicity of a new CTXΦ-negative, hemagglutinin/protease-defective El Tor strain as a Cholera vaccine candidate. Infect Immun 67:539-545
5. Butler SM, Nelson EJ, Chowdhury N et al (2006) Cholera stool bacteria repress chemotaxis to increase infectivity. Mol Microbiol 60:417-426
6. Butterton JR, Boyko SA, Calderwood SB (1993) Use of the Vibrio cholerae irgA gene as a locus for insertion and expression of heterologous antigens in cholera vaccine strains. Vaccine 11:1327-1335
7. Butterton JR, Beattie DT, Gardel CL et al (1995) Heterologous antigen expression in Vibrio cholerae vector strains. Infect Immun 63:2689-2696
8. Butterton JR, Ryan ET, Acheson DW et al (1997) Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains. Infect Immun 65:2127-2135
9. Camilli A, Mekalanos JJ (1995) Use of recombinase gene fusions to identify Vibrio cholerae genes induced during infection. Mol Microbiol 18:671-683
10. Chen I, Finn TM, Yanqing L et al (1998) A recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor. Infect Immun 66:1648-1653
11. Chiang SL, Mekalanos JJ (1998) Use of signature-tagged transposon mutagenesis to identify Vibrio cholerae genes critical for colonization. Mol Microbiol 27:797-805
12. Cohen MB, Giannella RA, Bean J et al (2002) Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun 70:1965-1970
13. Curtis III R, Kelly SM, Gulig PA et al (1989) Selective delivery of antigens by recombinant bacteria. Curr Top Microbiol Immunol 146:35-39
14. Eko FO, Witte A, Huter V et al (1999) New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine 17:1643-1649
15. Eko FO, Mayr UB, Attridge SR et al (2000) Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili. J Biotechnol 83:115-123
16. Eko FO, Schukovskaya T, Lotzmanova EY et al (2003) Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine 21:3663-3674
17. Eko FO, He Q, Brown T et al (2004) A novel recombinant multisubunit vaccine against Chlamydia. J Immunol 173:3375-3382
18. Fasano A, Baudry B, Pumplin DW et al (1991) Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci USA 88:5242-5246
19. Favre D, Lüdi S, Stoffel M et al (2006) Expression of enterotoxigenic Escherichia coli colonization factors in Vibrio cholerae. Vaccine 24:4354-4368
20. Finkelstein RA (1992) Cholera enterotoxin (choleragen): a historical perspective. In: Barua D, Greenough WB (eds) Cholera. Plenum Medical Book Company, New York, pp 155-187
21. Fontana MR, Monaci E, Yanqing L et al (2001) IEM101, a naturally attenuated Vibrio cholerae strain as carrier for genetically detoxified derivatives of cholera toxin. Vaccine 19:75-85
22. García L, Jidy MD, Garcia H et al (2005) The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 73:3018-3024
23. Gentschev I, Mollenkopf H, Sokolovic Z et al (1996) Development of antigen-delivery systems, based on the Escherichia coli hemolysin secretion pathway. Gene 179:133-140
24. Gentschev I, Dietrich G, Spreng S et al (2001) Recombinant attenuated bacteria for the delivery of subunit vaccines. Vaccine 19:2621-2628
25. Gentschev I, Dietrich G, Goebel W (2002) The E. coli α-hemolysin secretion system and its use in vaccine development. Trends Microbiol 10:39-44
26. Ghorpade A, Garg LC (1996) Efficient expression, processing and secretion of a biologically active mammalian protein in Vibrio cholerae. FEBS Lett 387:167-170
27. Häse CC, Finkelstein RA (1991) Cloning and nucleotide sequence of the Vibrio cholerae hemagglutinin/protease (HA/protease) gene and construction of an HA/protease-negative strain. J Bacteriol 173:3311-3317
28. Hazra A, Silva AJ, Benitez JA (2007) Expression of foreign proteins in a Vibrio cholerae vaccine strain using the stationary phase hemagglutinin/protease promoter. Biotechnol Lett 29:1093-1097
29. Herrington DA, Hall RH, Losonsky GA et al (1988) Toxin, the toxin co-regulated pili and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 168:1487-1492
30. Ifere G, He Q, Igietseme JU et al (2007) Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine. J Microbiol Immunol Infect 40:188-200
31. Jain V, Mekalanos JJ (2000) Use of lambda phage S and R gene products in an inducible lysis system for Vibrio cholerae- and Salmonella enterica serovar typhimurium-based DNA vaccine delivery systems. Infect Immun 68:986-989
32. Jobling MG, Holmes RK (1992) Fusion proteins containing the A2 domain of cholera toxin assemble with B polypeptides of cholera toxin to form immunoreactive and functional holotoxin-like chimeras. Infect Immun 60:4915-4924
33. John M, Crean TI, Calderwood SB et al (2000) In vitro and in vivo analyses of constitutive and in vivo-induced promoters in attenuated vaccine and vector strains of Vibrio cholerae. Infect Immun 68:1171-1175
34. Kaper JB, Morris Jr G, Levine MM (1995) Cholera. Clin Microbiol Rev 8:48-86
35. Kenner JR, Coster TS, Taylor DN et al (1995) Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis 172:1126-1129
36. Lee SH, Hava DL, Waldor MK et al (1999) Regulation and temporal expression patterns of Vibrio cholerae virulence genes during infection. Cell 99:625-634
37. Lee SH, Butler SM, Camilli A (2001) Selection for in vivo regulators of bacterial virulence. Proc Natl Acad Sci USA 98:6889-6894
38. Levine MM, Tacket CO (1994) Recombinant live cholera vaccines. In: Wachsmuth IK, Blake PA, Olsvik O (eds) Vibrio cholerae and cholera: molecular to global perspective. Amer. Soc. Microbiol., Washington, pp 395-413
39. Levine MM, Black RE, Clements ML et al (1984) Evaluation in humans of the attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun 43:512-522
40. Lin W, Fullner KJ, Clayton R et al (1999) Identification of a Vibrio cholerae RTX toxin gene cluster that is tightly linked to the cholera toxin prophage. Proc Natl Acad Sci USA 96:1071-1076
41. Macmillan L, Ifere GO, He Q et al (2007) A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. FEMS Immunol Med Microbiol 49:46-55
42. Michalski J, Galen JE, Fasano A et al (1993) CVD110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain. Infect Immun 61:4462-4468
43. Osorio CG, Crawford JA, Michalski JA et al (2005) Second-generation recombination-based in vivo expression technology for large-scale screening for Vibrio cholerae genes induced during infection of the mouse small intestine. Infect Immun 73:972-980
44. Peltola H, Siitonen A, Kyronseppa H et al (1991) Prevention of traveler's diarrhea by oral B-subunit/whole-cell cholera vaccine. Lancet 338:1285-1289
45. Pouwels PH, Leer RJ, Boersma WJ (1996) The potential of Lactobacillus as a carrier for oral immunization: development and preliminary characterization of a vector system for targeted delivery of antigens. J Biotechnol 44:183-192
46. Pouwels PH, Leer RJ, Shaw M et al (1998) Lactic acid bacteria as antigen delivery vectors for oral immunization purposes Int. J Food Microbiol 41:155-167
47. Qadri F, Chowdhury MI, Faruque SM et al (2005) Randomized, controlled study of the safety and immunogenicity of Perú-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis 192:573-579
48. Qadri F, Chowdhury MI, Faruque SM et al (2007) Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 25:231-238
49. Richie EE, Punjabi NH, Sidharta YY et al (2000). Efficacy of single dose live oral vaccine CVD 103-HgR in north Jakarta, Indonesia, a cholera-endemic area. Vaccine 18:2399-2410
50. Robert A, Silva AJ, Benítez JA et al (1996) Tagging a Vibrio cholerae El Tor candidate vaccine strain by disruption of its hemagglutinin/protease gene using a novel reporter gene: Clostridium thermocellum endoglucanase A. Vaccine 14:1517-1522
51. Rollins SM, Peppercorn A, Hang L et al (2005) In vivo induced antigen technology (IVIAT). Cell Microbiol 7:1-9
52. Ryan ET, Butterton JR, Smith RN et al (1997a) Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun 65:2941-2949
53. Ryan ET, Butterton JR, Zhang T et al (1997b) Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the Cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice. Infect Immun 65:3118-3125
54. Ryan ET, Crean TI, John M et al (1999) In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae. Infect Immun 67:1694-1701
55. Ryan ET, Crean TI, Kochi SK et al (2000) Development of a ΔglnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae. Infect Immun 68:221-226
56. Sanchez J, Svennerholm AM, Holmgren J (1988). Genetic fusion of a non-toxic heat-stable enterotoxin-related decapeptide antigen to cholera toxin B-subunit. FEBS Lett 241:110-114
57. Sanchez J, Johansson S, Löwenadler B et al (1990) Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination. Res Microbiol 141:971-979
58. Schödel F, Will H, Johansson S et al (1991) Synthesis in Vibrio cholerae and secretion of hepatitis B virus antigens fused to Escherichia coli heat-labile enterotoxin B subunit. Gene 99:255-259
59. Shata MT, Srtevceva L, Agwale S et al (2000) Recent advances with recombinant bacterial vectors. Mol Med Today 6:66-71
60. Silva AJ, Benitez JA (2005) Th1-type immune response to a Coccidioides immitis antigen delivered by an attenuated strain of the non-invasive enteropathogen Vibrio cholerae. FEMS Immunol Med Microbiol 43:393-398
61. Silva AJ, Mohan A, Benitez JA (2003) Cholera vaccine candidate 638: Intranasal immunogenicity and expression of a foreign antigen from the pulmonary pathogen Coccidioides immitis. Vaccine 21:4715-4721
62. Silva AJ, Leitch GJ, Camilli A et al (2006) Contribution of hemagglutinin/protease and motility to the pathogenesis of El Tor biotype cholera. Infect Immun 74:2072-2079
63. Sizemore DR, Branstrom AA, Sadoff JC (1997) Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization. Vaccine 15:804-807
64. Spreng S, Dietrich S, Niewiesk S et al (2000) Novel bacterial system for delivery of recombinant protein or DNA. FEMS Immunol Med Microbiol 27:299-304
65. 2 domain of cholera toxin. Infect Immun 66:462-468
66. Szostak MP, Lubitz W (1991) Recombinant bacterial ghosts as multivaccine vehicles. Vaccine 91: modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor Laboratory Press, Cold Spring Harbor
67. Tacket CO, Losonsky G, Nataro JP et al (1993) Safety and immunogenicity of live oral cholera vaccine candidate CVD110, a ΔctxAΔzotΔace derivative of El Tor Ogawa Vibrio cholerae. J Infect Dis 168:1536-1540
68. Trach DD, Clemens JD, Ke NT et al (1997) Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349:231-235
69. Trucksis M, Galen JE, Michalski J et al (1993) Accessory cholera enterotoxin (Ace), the third toxin of a Vibrio cholerae virulence cassette. Proc Natl Acad Sci USA 90:5267-5271
70. Valle E, Ledon T, Cedre B et al (2000) Construction and characterization of a non-proliferative El Tor cholera vaccine candidate derived from strain 638. Infect Immun 68:6411-6418
71. Van Loon FP, Clemens JD, Chakraborty J et al (1996) Field trial of inactivated oral cholera vaccines in Bangladesh: results from a 5 years follow-up. Vaccine 14:162-166
72. Waldor MK, Mekalanos JJ (1996) Lysogenic conversion by a filamentous phage encoding cholera toxin. Science 272:1910-1914
73. Witte A, Blasi U et al (1990) Phi X174 protein E-mediated lysis of Escherichia coli. Biochemie 72:191-200
74. Xu Q, Dziejman M, Mekalanos JJ (2003) Determination of the transcriptome of Vibrio cholerae during intraintestinal growth and midexponential phase in vitro. Proc Natl Acad Sci USA 100:1286-1291